#London #United Kingdom #Healthcare Conference #CytoSorbents #Blood Purification

CytoSorbents to Attend the 2026 Jefferies Global Healthcare Conference

CytoSorbents Corporation (NASDAQ: CTSO), a pioneer in blood purification technologies for life-threatening conditions, will be making a significant presence at the 2026 Jefferies Global Healthcare Conference in London. This event, renowned for gathering key players in the healthcare investment sector, provides a platform for CytoSorbents' leadership to engage directly with potential investors and stakeholders.

Scheduled for November 16-18, 2026, the conference is an essential event for health-conscious investors looking to explore advancements in critical care and cardiac medicine. The company's Chief Executive Officer, Dr. Phillip Chan, and Chief Financial Officer, Mr. Peter Mariani, will be partaking in one-on-one meetings, allowing attendees a unique opportunity to learn more about their innovative blood purification technologies.

The Jefferies Global Healthcare Conference, now in its 17th year, presents an exceptional opportunity for attendees to network with a variety of healthcare professionals, including C-suite executives, private equity investors, service providers, and industry strategists across diverse sectors such as pharmaceuticals, biotech, medical technology, and digital health. With over 300,000 devices utilized globally, CytoSorbents stands at the forefront of transforming patient care through advanced blood purification methods.

About CytoSorbents and Its Technologies

CytoSorbents Corporation specializes in addressing life-threatening conditions through advanced blood purification techniques. Its flagship product, CytoSorb®, is a significant advancement in managing severe medical situations, particularly in intensive care units and during cardiac surgeries. This product employs patented biocompatible polymer beads designed to purify blood by removing harmful substances that can lead to severe consequences for patients.

In such medical scenarios, the removal of inflammatory agents or excess blood thinners is crucial to improving patient outcomes. For instance, CytoSorb® is utilized to extract cytokines and toxins during operations where patients risk severe bleeding due to anticoagulant therapy. Its operational prowess lies in its ability to actively eliminate contaminants from blood through sophisticated pore capture and surface adsorption technologies. These processes have notably improved patient management in critical conditions, encompassing diseases like sepsis, liver failure, and acute respiratory distress syndrome, among others.

Moreover, CytoSorbents is engaged in developing new products designed to address specific medical needs. For instance, their investigational device, the DrugSorb®-ATR, is aimed at minimizing the risks associated with blood thinners in high-risk surgeries, exemplifying the company's commitment to innovation in critical care.

Engaging with Investors

Attending the Jefferies Global Healthcare Conference not only places CytoSorbents in the spotlight but also underscores its dedication to expanding its reach within the healthcare community. Investors are encouraged to schedule meetings through the conference website or contact the investor relations team of CytoSorbents directly to discuss the company's future prospects and strategies more intimately. By participating in such events, CytoSorbents aims to fortify its connections and highlight its significant contributions to improving patient outcomes through technology.

In conclusion, CytoSorbents Corporation is poised to leverage the Jefferies Global Healthcare Conference as a strategic platform for engaging with investors and stakeholders. As the company continues to innovate and expand its portfolio of products, it remains focused on addressing the challenges posed by severe medical conditions through its advanced blood purification technologies.

For more information about CytoSorbents Corporation and its innovative solutions, visit their official website and stay updated through their social media channels.